OptiBiotix Health (LSE:OPTI) announced it has disposed of 7.5m shares in SkinBioTherapeutics, generating cash proceeds of £675,000.
The company, which develops microbiome-modulating ingredients and products, said the cash will be used for general working capital and is expected to provide runway into H1 2027.
Following the sale OptiBiotix’s holding in SkinBioTherapeutics stands at 5.7m shares, representing 2.2% of SkinBioTherapeutics’ issued share capital at the date of the announcement.
